Centre Eugène Marquis

Centre Eugène Marquis is the Centre de Lutte Contre le Cancer for Rennes and Brittany, one of the 18 Unicancer centres in France. It provides medical oncology, radiotherapy, nuclear medicine and supportive care on the Pontchaillou campus shared with the CHU de Rennes, and its research groups work with Inserm and the University of Rennes on radiotherapy physics, medical imaging and cancer genomics. The centre is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre and coordinates regional cancer research through the Breton cancer network.

Location

Rennes, FR

Type

cancer center

Website

www.centre-eugene-marquis.fr

Newsweek 2026 oncology rank

Not in top 300 listing used

OnCo score

#496 · 6 points (0 Newsweek + 0 NCI + 6 from 3 linked objects) · ranking

Research output

From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.

Matched to Centre Eugène Marquis, including child institutions. 253 works · 3,051 citations · 69% open access · 21% clinical trials · 2% reviews.

Oncology works per year

572022

522023

572024

492025

382026

Most works

Most cited

Work	Journal	Year	Citations
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial 10.1038/s41591-023-02478-2 · open access	Nature Medicine	2023	392
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial 10.1016/j.annonc.2023.05.005 · open access	Annals of Oncology	2023	364
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer 10.1016/j.annonc.2023.05.008 · open access	Annals of Oncology	2023	311
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer 10.1038/s41523-022-00467-1 · open access	npj Breast Cancer	2022	112
Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY) conference abstract · 10.1158/1538-7445.sabcs21-pd8-02	Cancer Research	2022	108
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial 10.1038/s41591-023-02572-5 · open access	Nature Medicine	2023	101
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial 10.1159/000527175 · open access	Liver Cancer	2022	79
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma 10.1136/jitc-2022-004668 · open access	Journal for ImmunoTherapy of Cancer	2022	67
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis 10.1038/s41523-022-00439-5 · open access	npj Breast Cancer	2022	64
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging 10.1148/radiol.210518	Radiology	2022	59
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias 10.1016/j.ctrv.2022.102452 · open access	Cancer Treatment Reviews	2022	59
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer 10.1038/s41416-024-02766-9 · open access	British Journal of Cancer	2024	57
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer 10.1038/s41523-024-00635-5 · open access	npj Breast Cancer	2024	49
LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial 10.1016/j.annonc.2022.03.277 · open access	Annals of Oncology	2022	48
LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) 10.1016/j.annonc.2022.08.025 · open access	Annals of Oncology	2022	40

Programmes

3top

Radiotherapy physics
Nuclear medicine
Cancer genomics

People

1top

Renaud de Crevoisier

Directeur Général (Director General), Centre Eugène Marquis

OncologyCancer centre managementAcademic medicine

Professor of medicine who directs Centre Eugène Marquis, the regional comprehensive cancer centre for Brittany in Rennes.

Connected

4top

Institution
Institut du Cancer de Montpellier (ICM)
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre François Baclesse
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Jean Perrin
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Henri Becquerel
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Institut de Cancérologie de l'Ouest (ICO)
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Cancer Institute AP-HP Nord, Université Paris Cité
Shares Centre Georges-François Leclerc, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Person
Charles Coutant
Shares Centre Georges-François Leclerc, Organisation of European Cancer Institutes.
Institution
Hospital Universitario Fundación Jiménez Díaz
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.

Research output

Programmes

People

Connected

Similar pages

companies

institutions

people

Centre Eugène Marquis

Research output

Programmes

People

Connected

Similar pages

companies

institutions

people

Centre Eugène Marquis

Overview

Research output

Programmes

People

Connected

Similar pages

companies

institutions

people

Centre Eugène Marquis

Overview

Research output

Programmes

People

Connected

Similar pages

companies

institutions

people